A San Francisco-based immunology company announced new preclinical research highlighting novel mechanisms by which SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) enters host cells and identifying how auxiliary receptors may impact the clinical efficacy of monoclonal antibodies (mAbs).
Read More
![](https://covid19.healthcare.pro/wp-content/uploads/2021/04/covid-19-4922384-1.jpg)